WS Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$31.6M Buy
200,000
+50,000
+33% +$6.76M 2.77% 11
2026
Q1
$19.2M Buy
150,000
+20,000
+15% +$2.5M 1.69% 20
2025
Q4
$15.9M Buy
130,000
+53,543
+70% +$6.14M 1.3% 23
2025
Q3
$7.66M Hold
76,457
0.83% 31
2025
Q2
$6.34M Hold
76,457
0.88% 29
2025
Q1
$6.2M Sell
76,457
-23,543
-24% -$2.1M 0.69% 26
2024
Q4
$9.01M Hold
100,000
0.84% 27
2024
Q3
$9.88M Hold
100,000
0.69% 31
2024
Q2
$9.27M Sell
100,000
-25,000
-20% -$2.24M 0.68% 35
2024
Q1
$11.9M Sell
125,000
-25,000
-17% -$2.32M 0.75% 32
2023
Q4
$13.4M Hold
150,000
0.8% 34
2023
Q3
$11M Buy
150,000
+30,000
+25% +$2.4M 0.88% 34
2023
Q2
$9.98M Sell
120,000
-80,000
-40% -$6.69M 0.84% 33
2023
Q1
$15.2M Buy
200,000
+100,000
+100% +$8.3M 1.61% 19
2022
Q4
$8.3M Hold
100,000
0.71% 35
2022
Q3
$7.93M Sell
100,000
-70,000
-41% -$5.9M 0.72% 32
2022
Q2
$12.6M Buy
+170,000
New +$12.8M 1.03% 22

Other funds holding XBI

WS Management's XBI Position: Q2 2026 in Review

WS Management increased its State Street SPDR S&P Biotech ETF (XBI) stake by 33% in Q2 2026, buying an estimated $6.76M and bringing the position to 200,000 shares worth $31.6M. The position accounts for 2.77% of the portfolio, ranked #11.

WS Management first reported a position in XBI in Q2 2022 and has held it in 17 quarters since. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

  • WS Management held 200,000 shares of State Street SPDR S&P Biotech ETF worth $31.6M as of Q2 2026.
  • WS Management bought 50,000 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $6.76M.
  • State Street SPDR S&P Biotech ETF made up 2.77% of WS Management's portfolio in Q2 2026, its #11 holding.
  • WS Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2022 and has held it in 17 quarters since.
  • 933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on WS Management's 13F filing for Q2 2026, filed 14 Aug 2026.